Cannabix Technologies Appoints VP of Technology Development
Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety
VANCOUVER, British Columbia, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace is pleased to report that Dr. Moe Paknahad has joined the Company as VP of Technology Development. Dr. Paknahad will help direct product development of Cannabix’s THC breathalyzer devices. Dr. Paknahad is an Electrical Engineer who has spent last 10 years on research and development and product development in biomedical and environmental monitoring devices with skills in prototyping, piloting and commercialization.
Dr. Paknahad received his PhD in electrical engineering at the University of British Columbia (UBC) and completed his post-doctorate at the University of Toronto. He is a specialist in the areas of microfluidics, machine olfaction, sensors, organ-on-chip and lab-on-chip technologies. More recently he served as a product development specialist at CellScale Biomaterials and VitroFlo based in Ontario developing organ-on-chip in-vitro devices for drug screening purposes. In addition, he served as a technical lead and co-founder of early stage company developing energy harvesting technology. Dr. Paknahad played a significant role at UBC helping invent microfluidic gas analysis technology which is used for different applications ranging from human breath analysis to gas leakage detection in natural gas infrastructures.
Dr. Raj Attariwala stated, “Dr. Paknahad has deep knowledge of sensor technologies, pilot prototype production as well as commercialization and will be a great addition to our technical team for both microfluidic technologies and FAIMS.”
The Company has granted 200,000 stock options exercisable at $.80 for period of 2 years.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Source: GlobeNewswire
(February 11, 2020 - 8:45 AM EST)
